5 most popular innovation stories in Houston this week

what's trending

Houston-based BrainCheck has expanded into its own office space, innovators to know, and The Ion names new leadership — here are this week's top stories. Photo courtesy of BrainCheck

Editor's note: This week's top stories include new office space for a growing Houston health tech company, an energy software-as-a-service startup raises more money than it expected, and more trending innovation news.

3 Houston innovators to know this week

This week's innovators to know are focused on bringing startup programming and venture capital to Houston. Courtesy photos

This past week has been full of exciting innovation news in Houston — from big fundraising round closings to a new unicorn coming out of the Bayou City.

Houston innovators to know this week include a new program director for Houston's newest startup accelerator, a venture capital fund leader, and more. Continue reading.

Houston health tech startup moves into new office amid major growth

BrainCheck has moved to a new office as it grows its team and expands its product. Natalie Harms/InnovationMap

Following a series A round of fundraising, a Houston digital health startup is on a bit of a hiring spree, leading to new office space the company has room to grow into.

BrainCheck, which was founded in 2015 by neuroscientist David Eagleman, is a cognitive assessment startup that has developed a software tool for primary care doctors to use to assess their patients' cognitive health so that they can more quickly diagnose and treat them for maladies like dementia.

The 19-person company headquartered in Houston — with a secondary office in Austin focused on product development — has relocated its operations from coworking space in the Texas Medical Center to an office in the Rice Village area. The move was made possible by an $8 million series A financing round that closed in October. Continue reading.

TMCx company receives investment from Houston VC, UH program recognized, and more innovation news

TMCx

A TMCx company has raised money in Houston, UH's online program named best in the nation, and more Houston innovation news. Courtesy of TMCx

Houston's innovation ecosystem has seen a busy January so far — the city has claimed a unicorn in High Radius, The Ion has named a series of new execs, and so much more.

Given this influx of news, you might've missed some other Houston innovation headlines, like UH being recognized for its online master's program, recent fundings, and Texas being named a state for female entrepreneurs. Here's a few short stories to catch you up. Continue reading.

The Ion Houston names 3 new execs to its team

Jan E. Odegard, Deanea LeFlore, and Chris Valka have been named senior directors at The Ion. Photos courtesy of The Ion

The Ion, an entrepreneurship center being developed in the old Sears building in Midtown by the Rice Management Company, has named three new senior directors to its team.

Deanea LeFlore, Jan E. Odegard, and Chris Valka are the three newly named leaders of the organization, effective immediately. They join — and will report to — Gabriella Rowe, who was named executive director in October.

"To grow the Houston innovation system and spearhead our mission for the Ion we've hired three new leaders with fresh perspectives, ideas, and approaches," says Allison K. Thacker, president and chief investment officer of the Rice Management Company, in a news release. "Each individual has a unique connection to Houston and the Ion, and we're thrilled to have them join our effort to build on the culture of innovation across our city, and within the community we're cultivating at the Ion." Continue reading.

Houston-based oil and gas software company raises $1.6 million

XXXL pumpjack silhouettes

Houston-based M1neral has raised $1.6 million in an oversubscribed pre-seed round. Getty Images

A Houston energy tech startup that's digitally optimizing the minerals rights buying and selling process has closed an oversubscribed pre-seed financing round to the tune of $1.6 million.

M1neral's round was co-led by Amnis Ventures and Pheasant Energy, among a few other select investors and strategic partners. The company was co-founded by Jacob Avery, Kyle Chapman, and Shawn Cutter.

"Amnis Ventures is delighted to co-lead the current round of funding in M1neral. The founders come with deep knowledge of oil and gas, coupled with proven, delivered technology implementations in the energy space," says Manuel Silva III, president of Amnis Ventures Inc., in a press release. "The M1neral platform will bring age-old upstream oil and gas processes into the technology revolution of the 21st century that we have come to expect in other sectors." Continue reading.

Jan E. Odegard, Deanea LeFlore, and Chris Valka have been named senior directors at The Ion. Photos courtesy of The Ion

The Ion Houston names 3 new execs to its team

new hires

The Ion, an entrepreneurship center being developed in the old Sears building in Midtown by the Rice Management Company, has named three new senior directors to its team.

Deanea LeFlore, Jan E. Odegard, and Chris Valka are the three newly named leaders of the organization, effective immediately. They join — and will report to — Gabriella Rowe, who was named executive director in October.

"To grow the Houston innovation system and spearhead our mission for the Ion we've hired three new leaders with fresh perspectives, ideas, and approaches," says Allison K. Thacker, president and chief investment officer of the Rice Management Company, in a news release. "Each individual has a unique connection to Houston and the Ion, and we're thrilled to have them join our effort to build on the culture of innovation across our city, and within the community we're cultivating at the Ion."

To focus on the Ion's Academic Partner Network, Jan E. Odegard has been appointed senior director of industry and academic partners. Odegard's background includes research and leadership at Rice University in computing. Odegard will also oversee The Ion's labs, which include human/robotics interaction lab, an immersive reality lab and an industrial prototyping lab.

Deanea LeFlore has been named senior director of community and corporate engagement. Like Rowe, LeFlore had a similar role at Station Houston before this new position. Before that, she spent most of her career working for the city of Houston and served under four Mayors over 17 years.

Lastly, Chris Valka, has been hired as senior director of operations, overseeing finance, accounting, human resources, operations, and facilities management. Prior to this position, Valka served in the president's cabinet overseeing a similar spectrum of responsibilities at the University of St. Thomas.

"As we prepare for The Ion's opening in early 2021, we are excited to welcome Deanea LeFlore, Dr. Jan E. Odegard, and Chris Valka, to our growing team," says Rowe in the release. "I am excited to see what this diverse group of experts will bring to our efforts to build an inclusive innovation hub in a tech-forward environment that promotes all that is great about Houston."

The 270,000-square-foot Ion building broke ground in July of last year and is slated to open in 2021. Recently, the organization announced its first programming partner — Rice University's Glasscock School of Continuing Studies, and select courses have already begun.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings